Disclosures for "Integrated Genomic, Proteomic, and Transcriptomic Profiling Support Cathepsin-B as a Drug Repurposing Target in Cerebral Small Vessel Disease "
-
Dr. Rivier has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pyxis Partners.
-
Dr. Huo has nothing to disclose.
-
Mr. Clocchiatti-Tuozzo has nothing to disclose.
-
Dr. Renedo has nothing to disclose.
-
Dr. Sharma has received research support from NIH. Dr. Sharma has received intellectual property interests from a discovery or technology relating to health care.
-
Sam Payabvash has nothing to disclose.
-
Dr. Rangaraju has nothing to disclose.
-
Author has nothing to disclose
-
Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Sansing has nothing to disclose.
-
The institution of Dr. Falcone has received research support from NIH. The institution of Dr. Falcone has received research support from AHA.